close 76% inwestorów detalicznych traci pieniądze podczas handlu CFD z tym dostawcą. Inwestowanie wiąże się z ryzykiem i nie jest odpowiednie dla wszystkich inwestorów. Kontrakty CFD są złożonymi instrumentami i wiążą się z dużym ryzykiem szybkiej utraty środków pieniężnych z powodu dźwigni finansowej. 76% rachunków inwestorów detalicznych notuje stratę pieniędzy podczas handlu kontraktami CFD z tym dostawcą. Upewnij się, czy rozumiesz, jak działają kontrakty CFD, i czy możesz pozwolić sobie na wysokie ryzyko utraty pieniędzy.
Change languagePolski
Dashboard

LLY

779.86

-1.89%↓

JNJ

152.52

+0.03%↑

ABBV

185.27

-0.73%↓

NVO

68.23

+1.32%↑

UNH

307.35

+1.39%↑

LLY

779.86

-1.89%↓

JNJ

152.52

+0.03%↑

ABBV

185.27

-0.73%↓

NVO

68.23

+1.32%↑

UNH

307.35

+1.39%↑

LLY

779.86

-1.89%↓

JNJ

152.52

+0.03%↑

ABBV

185.27

-0.73%↓

NVO

68.23

+1.32%↑

UNH

307.35

+1.39%↑

LLY

779.86

-1.89%↓

JNJ

152.52

+0.03%↑

ABBV

185.27

-0.73%↓

NVO

68.23

+1.32%↑

UNH

307.35

+1.39%↑

LLY

779.86

-1.89%↓

JNJ

152.52

+0.03%↑

ABBV

185.27

-0.73%↓

NVO

68.23

+1.32%↑

UNH

307.35

+1.39%↑

Strona główna・Stock List・Nektar Therapeutics
Search

Nektar Therapeutics

Open

26.15 -5.66

Buy

Price update 27 cze 2025, 18:11 UTC

BuySell

Overview

Share price change

24h

Current

Min

25.22

Max

29.74

Key metrics

By Trading Economics

Income

-58M

-51M

Sales

-19M

10M

EPS

-0.24

Profit margin

-486.444

Employees

61

EBITDA

-58M

-41M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+238.26% upside

Dividends

By Dow Jones

Next Earnings

7 sie 2025

Market Stats

By TradingEconomics

Market Cap

118M

Previous open

31.81

Previous close

26.15

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

0.5949 / 0.7406 Support & Resistance

Nektar Therapeutics Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

26 cze 2025, 23:49 UTC

Earnings

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

DJ

Read

26 cze 2025, 22:19 UTC

Acquisitions, Mergers, Takeovers

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

DJ

Read

26 cze 2025, 21:30 UTC

Earnings

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

DJ

Read

26 cze 2025, 21:07 UTC

Earnings

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

DJ

Read

26 cze 2025, 23:49 UTC

Market Talk

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

DJ

Read

26 cze 2025, 23:39 UTC

Market Talk

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

DJ

Read

26 cze 2025, 23:34 UTC

Acquisitions, Mergers, Takeovers

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

DJ

Read

26 cze 2025, 23:33 UTC

Acquisitions, Mergers, Takeovers

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

DJ

Read

26 cze 2025, 23:32 UTC

Acquisitions, Mergers, Takeovers

Wesfarmers Will No Longer Receive Earnings From BWP Management

DJ

Read

26 cze 2025, 23:32 UTC

Acquisitions, Mergers, Takeovers

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

DJ

Read

26 cze 2025, 23:31 UTC

Acquisitions, Mergers, Takeovers

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

DJ

Read

26 cze 2025, 23:31 UTC

Acquisitions, Mergers, Takeovers

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

DJ

Read

26 cze 2025, 23:30 UTC

Acquisitions, Mergers, Takeovers

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

DJ

Read

26 cze 2025, 23:29 UTC

Acquisitions, Mergers, Takeovers

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

DJ

Read

26 cze 2025, 23:19 UTC

Acquisitions, Mergers, Takeovers

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

DJ

Read

26 cze 2025, 22:06 UTC

Earnings

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

DJ

Read

26 cze 2025, 21:15 UTC

Earnings

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

DJ

Read

26 cze 2025, 21:07 UTC

Acquisitions, Mergers, Takeovers

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

DJ

Read

26 cze 2025, 21:07 UTC

Acquisitions, Mergers, Takeovers

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

DJ

Read

26 cze 2025, 21:07 UTC

Acquisitions, Mergers, Takeovers

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

DJ

Read

26 cze 2025, 21:07 UTC

Earnings

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

DJ

Read

26 cze 2025, 21:06 UTC

Acquisitions, Mergers, Takeovers

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

DJ

Read

26 cze 2025, 21:06 UTC

Acquisitions, Mergers, Takeovers

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

DJ

Read

26 cze 2025, 21:06 UTC

Market Talk

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

DJ

Read

26 cze 2025, 21:05 UTC

Acquisitions, Mergers, Takeovers

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

DJ

Read

26 cze 2025, 21:05 UTC

Acquisitions, Mergers, Takeovers

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

DJ

Read

26 cze 2025, 20:52 UTC

Earnings

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

DJ

Read

26 cze 2025, 20:51 UTC

Earnings

Correct: Nike 4Q Net $211M, Not $200M >NKE

DJ

Read

26 cze 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

DJ

Read

26 cze 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

DJ

Read

Peer Comparison

Price change

Nektar Therapeutics Forecast

Price Target

By TipRanks

238.26% upside

12 Months Forecast

Average 98.5 USD  238.26%

High 120 USD

Low 69 USD

Based on 6 Wall Street analysts offering 12 month price targets forNektar Therapeutics - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

6 ratings

4

Buy

1

Hold

1

Sell

Based on 6 analysts giving stock ratings to Nektar Therapeutics - Dist in the past 3 months.

Technical Score

By Trading Central

0.5949 / 0.7406Support & Resistance

Short Term

Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Intermediate Term

Strong Bearish Evidence

All events are bearish.

Long Term

Bearish Evidence

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

Other stocks from the sector

LLY

Eli Lilly and Co.

779.86

↓-1.89%

JNJ

Johnson and Johnson

152.52

↑ +0.03%

ABBV

AbbVie Inc

185.27

↓-0.73%

NVO

Novo Nordisk A-S

68.23

↑ +1.32%

UNH

UnitedHealth Group Inc

307.35

↑ +1.39%